AstraZeneca plans to invest $50 billion in US by 2030

Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US

Roche provides update on astegolimab in chronic obstructive pulmonary disease

The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks

AstraZeneca’s Tagrisso plus chemotherapy improves overall survival in EGFR-mutated advanced lung cancer

Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination

Neuberg Pulse partners with Dhoni to launch diagnostics centre in Ranchi

Neuberg group commits to invest over Rs. 100 crores to start diagnostics facilities across Jharkhand in the next 2-3 years

Kenvue collaborates with API to launch India’s first cough clinics

Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough

Brenntag Specialties Pharma offering phosphate-based excipients by Budenheim

Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes

Biocon Biologics expands diabetes portfolio with FDA approval of Kirsty

Corona Remedies acquires 7 brands from Bayer's pharma division in India

This marks the fourth acquisition by Corona Remedies from multinational corporations

Emcure Pharmaceuticals, Sanofi India ink distribution agreement to broaden reach of Sanofi's oral anti-diabetic drugs

Cupid invests in GII Healthcare Investment

GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India